Immucell (ICCC) Debt to Equity (2016 - 2025)
Immucell's Debt to Equity history spans 16 years, with the latest figure at $0.34 for Q4 2025.
- For Q4 2025, Debt to Equity fell 12.18% year-over-year to $0.34; the TTM value through Dec 2025 reached $0.34, down 12.18%, while the annual FY2025 figure was $0.34, 12.18% down from the prior year.
- Debt to Equity reached $0.34 in Q4 2025 per ICCC's latest filing, up from $0.32 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.48 in Q2 2024 to a low of $0.28 in Q4 2021.
- Average Debt to Equity over 5 years is $0.36, with a median of $0.34 recorded in 2025.
- Peak YoY movement for Debt to Equity: skyrocketed 44.53% in 2023, then plummeted 31.66% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.28 in 2021, then rose by 20.03% to $0.34 in 2022, then skyrocketed by 42.21% to $0.48 in 2023, then decreased by 20.03% to $0.38 in 2024, then fell by 12.18% to $0.34 in 2025.
- Per Business Quant, the three most recent readings for ICCC's Debt to Equity are $0.34 (Q4 2025), $0.32 (Q3 2025), and $0.33 (Q2 2025).